Haemonetics (DB:HAZ) - Stock Price, News & Analysis

HAZ Stock Overview

Haemonetics Corporation, a healthcare company, provides medical products and solutions.

HAZ fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	5/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 28.6% below our estimate of its fair value

Earnings are forecast to grow 27.44% per year

Earnings grew by 172.2% over the past year

Risk Analysis

Has a high level of debt

My Notes

New

Notes are coming soon

Haemonetics Corporation Competitors

Paul Hartmann

DB:PHH2

€806.2m

Carl Zeiss Meditec

XTRA:AFX

€11.9b

Eckert & Ziegler Strahlen- und Medizintechnik

XTRA:EUZ

€1.1b

Stratec

XTRA:SBS

€1.0b

Price History & Performance

Summary of all time highs, changes and price drops for Haemonetics
Historical stock prices
Current Share Price	US$80.50
52 Week High	US$85.50
52 Week Low	US$38.60
Beta	0.37
1 Month Change	9.52%
3 Month Change	0%
1 Year Change	87.21%
3 Year Change	-16.58%
5 Year Change	53.71%
Change since IPO	285.54%

Recent updates

Shareholder Returns

	HAZ	DE Medical Equipment	DE Market
7D	1.3%	-2.2%	-0.07%
1Y	87.2%	-14.5%	-8.7%

Return vs Industry: HAZ exceeded the German Medical Equipment industry which returned -19.3% over the past year.

Return vs Market: HAZ exceeded the German Market which returned -12.9% over the past year.

Price Volatility

Is HAZ's price volatile compared to industry and market?
HAZ volatility
HAZ Average Weekly Movement	5.5%
Medical Equipment Industry Average Movement	5.0%
Market Average Movement	5.2%
10% most volatile stocks in DE Market	10.2%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: HAZ is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: HAZ's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1971	2,821	Chris Simon	https://www.haemonetics.com

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Haemonetics Corporation Fundamentals Summary

How do Haemonetics's earnings and revenue compare to its market cap?
HAZ fundamental statistics
Market Cap	€4.19b
Earnings (TTM)	€79.19m
Revenue (TTM)	€997.34m

52.9x

P/E Ratio

4.2x

P/S Ratio

Is HAZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
HAZ income statement (TTM)
Revenue	US$1.08b
Cost of Revenue	US$491.12m
Gross Profit	US$592.60m
Other Expenses	US$506.55m
Earnings	US$86.05m

Last Reported Earnings

Oct 01, 2022

Next Earnings Date

Feb 07, 2023

Earnings per share (EPS)	1.70
Gross Margin	54.68%
Net Profit Margin	7.94%
Debt/Equity Ratio	112.3%

How did HAZ perform over the long term?

See historical performance and comparison

HAZ Stock Overview

Rewards

Risk Analysis

Haemonetics Corporation Competitors

DB:PHH2

€806.2m

XTRA:AFX

€11.9b

XTRA:EUZ

€1.1b

XTRA:SBS

€1.0b

Price History & Performance

Recent News & Updates

Investor sentiment improved over the past week

Haemonetics Corporation to Report Q3, 2023 Results on Feb 07, 2023

Second quarter 2023 earnings released: EPS: US$0.65 (vs US$0.29 in 2Q 2022)

Haemonetics Corporation Updates Revenue Guidance for the Year 2023

Haemonetics Corporation Appoints Maryanne Farris as Principal Accounting Officer

Haemonetics Corporation to Report Q2, 2023 Results on Nov 07, 2022

Recent updates

Investor sentiment improved over the past week

Haemonetics Corporation to Report Q3, 2023 Results on Feb 07, 2023

Second quarter 2023 earnings released: EPS: US$0.65 (vs US$0.29 in 2Q 2022)

Haemonetics Corporation Updates Revenue Guidance for the Year 2023

Haemonetics Corporation Appoints Maryanne Farris as Principal Accounting Officer

Haemonetics Corporation to Report Q2, 2023 Results on Nov 07, 2022

Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

Independent Director recently sold €580k worth of stock

First quarter 2023 earnings released: EPS: US$0.39 (vs US$0.087 loss in 1Q 2022)

Haemonetics Corporation (NYSE:HAE) announces an Equity Buyback for $300 million worth of its shares.

Haemonetics Corporation Announces Management Changes

Haemonetics Corporation to Report Q1, 2023 Results on Aug 10, 2022

Haemonetics Corporation, Annual General Meeting, Aug 05, 2022

CEO, President & Director recently sold €69k worth of stock

Haemonetics Corporation Announces Michelle L. Basil, Executive Vice President, General Counsel Has Decided to Transition, Effective October 31, 2022

Haemonetics Corporation Announces Retirement of Dan Goldstein as Vice President, Corporate Controller and Principal Accounting Officer, Effective August 9, 2022

Insider recently sold €61k worth of stock

Investor sentiment improved over the past week

Haemonetics Corporation Provides Earnings Guidance for the Fiscal Year 2023

Full year 2022 earnings released: EPS: US$0.85 (vs US$1.57 in FY 2021)

Haemonetics Corporation to Report Q4, 2022 Results on May 10, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Haemonetics Corporation Reaffirms Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: EPS US$0.29 (vs US$0.95 in 2Q 2021)

First quarter 2022 earnings released: US$0.087 loss per share (vs US$0.21 profit in 1Q 2021)

Independent Chairman Richard Meelia has left the company

Haemonetics Corporation(NYSE:HAE) dropped from Russell Midcap Index

Haemonetics Corporation(NYSE:HAE) dropped from Russell 1000 Dynamic Index

CEO, President & Director recently sold €59k worth of stock

Senior Vice President of Human Resources Jacqueline Scanlan has left the company

CEO, President & Director recently sold €123k worth of stock

Independent Director recently sold €66k worth of stock

Full year 2021 earnings released: EPS US$1.57 (vs US$1.51 in FY 2020)

Haemonetics Corporation Provides Earnings Guidance for the Fiscal Year 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: €112

Third quarter 2021 earnings released: EPS US$0.63 (vs US$0.59 in 3Q 2020)

Revenue beats expectations

Haemonetics Corporation(NYSE:HAE) dropped from Russell 2000 Defensive Index

Haemonetics Corporation Welcomes New FDA Guidance on Viscoelastic Testing During COVID-19 Pandemic

Haemonetics Corporation (NYSE:HAE) entered into a definitive agreement to acquire Cardiva Medical, Inc. for approximately $570 million.

Haemonetics Corporation to Report Q3, 2021 Results on Feb 02, 2021

Haemonetics Corporation Did Not Issue Earnings Guidance for the Full Year of Fiscal 2021

Revenue beats expectations

Second quarter 2021 earnings released: EPS US$0.95

Haemonetics Corporation to Report Q2, 2021 Results on Nov 04, 2020

Haemonetics Corporation Receives FDA Clearance for NexSys PCS® With Persona™ Technology

Haemonetics Corporation Did Not Provide Earnings Guidance for the Full Year of Fiscal 2021

First quarter earnings released

New 90-day low - €63.50

Haemonetics Corporation (NYSE:HAE) acquired enicor GmbH.

Haemonetics Corporation to Report Q1, 2021 Results on Aug 04, 2020

Haemonetics Corporation(NYSE:HAE) dropped from Russell 2000 Defensive Index

Haemonetics Corporation(NYSE:HAE) dropped from Russell 2000 Growth-Defensive Index

Haemonetics Corporation(NYSE:HAE) dropped from Russell 2000 Index

Shareholder Returns

Price Volatility

About the Company